Editas Medicine (EDIT) Metrics: History & Chart

Editas Medicine, Inc.(EDIT)

Biotechnology · Cambridge, MA

$2.80+0.00 (+0.18%)

Delayed quote: Oct 6, 2026, 10:10 AM EDT

About Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Cambridge, MA

87 employees

www.editasmedicine.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Gilmore O'Neill

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	+11.16%
30D Total Return	-13.62%
YTD Total Return	+36.10%
1Y Total Return	-28.83%
3Y Total Return	-61.09%
5Y Total Return	-92.70%
10Y Total Return	-81.98%
15Y Total Return	N/A
20Y Total Return	N/A

2026	+36.10%
2025	+61.42%
2024	-87.46%
2023	+14.21%
2022	-66.59%
2021	-62.13%
2020

CAGR TTM	-28.71%
CAGR 3Y	-26.99%
CAGR 5Y	-40.76%
CAGR 10Y	-15.75%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

EDIT Valuation Metrics

EDIT Stock Price Metrics

EDIT Dividend Metrics

EDIT Growth Rate Metrics

EDIT Discounted Cash Flow Metrics

EDIT Returns By Period

EDIT Yearly Returns

EDIT Average Annual Returns By Period (CAGR)

EDIT Revenue Metrics

EDIT PE Ratio Metrics

EDIT PS Ratio Metrics

EDIT PB Ratio Metrics

EDIT Price to Free Cash Flow Ratio Metrics

EDIT Debt to Equity Ratio Metrics

EDIT PEG Ratio Metrics

EDIT FCF Yield

EDIT Earnings Yield

EDIT EBITDA Yield

EDIT OCF Yield

EDIT EV/EBIT Ratio Metrics

EDIT EV/EBITDA Ratio Metrics

EDIT EV/Assets Ratio Metrics

EDIT EV/Sales Ratio Metrics

EDIT Current Ratio Metrics

EDIT Quick Ratio Metrics

EDIT ROIC Metrics

EDIT Return on Assets Metrics

EDIT Return on Equity Metrics

EDIT Net Profit Margin Metrics

EDIT Gross Profit Margin Metrics

EDIT Tax Rate Metrics

PS Ratio	7.08
PS Ratio Avg TTM	6.16
PS Ratio Avg 3Y	5.35
Current VS TTM Avg	+14.91%
Current VS 3Y Avg	+32.22%
Current VS 5Y Avg	-60.04%

PB Ratio	3.16
PB Ratio Avg TTM	22.82
PB Ratio Avg 3Y	4.75
Current VS TTM Avg	-86.15%
Current VS 3Y Avg	-33.51%
Current VS 5Y Avg	+65.35%

PFCF Ratio	87.02
PFCF Ratio Avg TTM	53.84
PFCF Ratio Avg 3Y	53.84
Current VS TTM Avg	+61.62%
Current VS 3Y Avg	+61.62%
Current VS 5Y Avg	+61.62%

Debt/Equity Ratio	0.15
Debt/Equity Ratio Avg TTM	4.37
Debt/Equity Ratio Avg 3Y	0.39
Current VS TTM Avg	-96.63%
Current VS 3Y Avg	-62.30%
Current VS 5Y Avg	+10.74%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	1.15%
FCF Yield Avg TTM	2.75%
FCF Yield Avg 3Y	2.75%
Current VS TTM Avg	-58.20%
Current VS 3Y Avg	-58.20%
Current VS 5Y Avg	-58.20%

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	0.70
Ev/Assets Ratio Avg TTM	0.83
Ev/Assets Ratio Avg 3Y	0.73
Current VS TTM Avg	-15.90%
Current VS 3Y Avg	-3.79%
Current VS 5Y Avg	-21.06%

Ev/Sales Ratio	3.54
Ev/Sales Ratio Avg TTM	3.64
Ev/Sales Ratio Avg 3Y	3.48
Current VS TTM Avg	-2.84%
Current VS 3Y Avg	+1.66%
Current VS 5Y Avg	-74.83%

Current Ratio	3.19
Current Ratio Avg TTM	3.12
Current Ratio Avg 3Y	3.84
Current VS TTM Avg	+2.23%
Current VS 3Y Avg	-17.08%
Current VS 5Y Avg	-49.87%

Quick Ratio	3.19
Quick Ratio Avg TTM	3.12
Quick Ratio Avg 3Y	3.84
Current VS TTM Avg	+2.23%
Current VS 3Y Avg	-17.08%
Current VS 5Y Avg	-49.87%

ROIC	(48.61%)
ROIC Avg 3Y	(86.74%)
ROIC Avg 5Y	(68.03%)
Current VS 3Y Avg	+43.96%
Current VS 5Y Avg	+28.54%
Current VS 10Y Avg	-32.47%

ROA	(31.15%)
ROA Avg TTM	(13.03%)
ROA Avg 3Y	(13.70%)
Current VS TTM Avg	-139.06%
Current VS 3Y Avg	-127.44%
Current VS 5Y Avg	-206.72%

ROE	(70.24%)
ROE Avg TTM	(328.40%)
ROE Avg 3Y	(164.50%)
Current VS TTM Avg	+78.61%
Current VS 3Y Avg	+57.30%
Current VS 5Y Avg	-26.59%

Net Profit Margin	(157.32%)
Net Profit Margin Avg TTM	(575.86%)
Net Profit Margin Avg 3Y	(693.18%)
Current VS TTM Avg	+72.68%
Current VS 3Y Avg	+77.30%
Current VS 5Y Avg	+76.92%

Gross Profit Margin	100.00%
Gross Pft Margin Avg TTM	(46.29%)
Gross Pft Margin Avg 3Y	(143.70%)
Current VS TTM Avg	+316.02%
Current VS 3Y Avg	+169.59%
Current VS 5Y Avg	+141.63%

Tax Rate	0.00%
Tax Rate Avg 3Y	N/A
Tax Rate Avg 5Y	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A